Completed PHASE2 INTERVENTIONAL 1-arm NCT00594256

Sodium Oxybate in Schizophrenia With Insomnia

Open Label, Pilot Study of Adjunctive Xyrem (Sodium Oxybate) for the Treatment of Schizophrenia and Associated Sleep Disturbances

Sponsor: Jazz Pharmaceuticals

Conditions Insomnia Related to Schizophrenia (307.42) Schizophrenia

Interventions Sodium Oxybate

Updated 9 times since 2017 Last updated: Jan 5, 2016 Started: May 31, 2008 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Insomnia Related to Schizophrenia (307.42) and Schizophrenia, this trial is completed. The trial is conducted by Jazz Pharmaceuticals and has accumulated 9 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jazz Pharmaceuticals
Nathan Kline Institute for Psychiatric Research

Data source: Nathan Kline Institute for Psychiatric Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orangeburg, United States